['t-cell lymphoma']
['bcd chemotherapy (bendamustine, carboplatin, dexamethasone)']

        Inclusion Criteria:

          1. Histologically proven aggressive T-cell Non-Hodgkin's lymphoma (NHL)

          2. Age 18 -75 years

          3. Ann Arbor stage II, III and IV (Appendix A)

          4. Relapsed or refractory cases to previous treatments

          5. Performance status (ECOG) ≤ 2 (Appendix B)

          6. At least one or more bidimensionally measurable lesion(s)

               -  ≥ 2 cm by conventional CT

               -  ≥ 1 cm by spiral CT

               -  skin lesion (photographs should be taken) ≥ 2 cm

               -  measurable lesion by physical examination ≥ 2 cm

          7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2DECHO without clinically
             significant abnormalities

          8. Adequate renal function: serum creatinine level < 2 mg/dL (177 μmol/L)

          9. Adequate liver functions: Transaminase (AST/ALT) < 3 X upper normal value (or < 5 x
             ULN in the presence of DLBCL involvement of the liver), Bilirubin < 2 X upper normal
             value (or < 5 x ULN in the presence of PTCL involvement of the liver)

         10. Adequate BM functions: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL
             and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow
             involvement by lymphoma

         11. A negative serum or urine pregnancy test prior to treatment must be available both for
             pre-menopausal women and for women who are < 1years after the onset of menopause.

         12. Informed consent

        Exclusion Criteria:

          1. ALK-positive anaplastic large cell lymphoma and Sezary syndrome.

          2. CNS or testis involvement.

          3. Previously treated with the regimen containing bendamustine or platinum agents.

          4. Any other malignancies within the past 5 years except curatively treated non-melanoma
             skin cancer or in situ carcinoma of cervix uteri

          5. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          6. Other serious illness or medical conditions

          7. Unstable cardiac disease despite treatment, myocardial infarction within 6 months
             prior to study entry

          8. History of significant neurologic or psychiatric disorders including dementia or
             seizures

          9. Active uncontrolled infection (viral, bacterial or fungal infection)

         10. Other serious medical illnesses

         11. Known hypersensitivity to any of the study drugs or its ingredients

         12. Concomitant administration of any other experimental drug under investigation, or
             concomitant chemotherapy, hormonal therapy, or immunotherapy.
      